RoulletJ.B., XueH., PappuA.S.Mevalonate availability affects human and rat resistance vessel function. J Clin Invest1995; 96: 239–44.
6.
GolperT.A., SwartzS.. Impaired renal mevalonate metabolism in nephrotic syndrome a stimulus for increased hepatic cholesterogenesis independent of GFR and hypoalbuminemiaMetabolism1981; 31: 471–6.
7.
ParkerT.S., McManaraD.J., BrownC.D.Plasma mevalonate as measure of cholesterol synthesis in man. J Clin Invest1984; 74: 795–804.
8.
ParkerT.S., McManaraD.J., BrownC.D.Mevalonic acid in human plasma: relationship of concentration and circadian rhyrhm to cholesterol synthesis rates in man. Proc Natl Acad Sci USA1982; 79: 3037–41.
9.
JonesP.J.H., PappuA.S., IllingworthD.R., LeitchC.A.. Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis. Eur J Clin Invest1992; 22: 609–13.
10.
YoshidaT., HondaA., TanakaN., MatsuzakiY., HeB., OsugaT.. Simultaneous determination of mevalonate and 7-alphydroxy-cholesterol in human plasma by gas chromatography-mass spectrometry as indices of cholesterol and bile acid bio-synthesis. J Cromatogr1993; 613: 185–93.
11.
ScoppolaA., MaherV.M.G., ThompsonG.R., RendellN.B., TaylorG.W.. Quantitation of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry. J Lipid Res1991; 32: 1057–60.
12.
BrownM.S., GoldsteinJ.L.. Multivalent feed-back regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res1980; 21: 505–17.
13.
CarlebergM., HjertmanM., WejdeL., LarssonO.. Mevalonate is essential for growth activation of human fibroblasts: evidence of a critical role of protein glycosylation in the prereplicative period. Experimental Cell Res1994; 212: 359–66.
14.
SomaM., BaettaR., De RenzisM.R.In vivo enhanced antitumor activity of carmustine (N,N'-bis(2-chloroethyl)-N-nitrosourea) by simvastatin. Cancer Res1995; 55: 597–602.
15.
MallatA., PreauxA.M., BlazejewskiS., DhumeausD., RosenbaumJ., MavierP.. Effect of simvastatin, and inhibitor of hydroxy-methylglutaryl coenzyme A reductase, on the growth of human Ito cells. Hepatology1994; 20: 1589–94.
16.
Quesney-HuneeusV., WileyM.H., SipersteinM.D.. Essential role for mevalorate synthesis in DNA replication. Proc Natl Acad Sci USA1979; 76: 5056–60.
17.
O'DonnelM.P., KasiskeB.L., KimY., AtluruD., KeaneW.F.. Lovastatin inhibit proliferation of rat mesangial cells. J Clin Invest1993; 91: 83–7.
Quesney-HuneeusV., GalickH.A., SipersteinM.D., EricksonS.K., SpencerT.A., NelsonJ.A.. The dual role of mevalonate in the cell cycle. J Biol Chem1983; 258: 378–85.
20.
FairbanksK.P., WitteL.D., GoodmanD.S.. Relationship between mevalonate and mitogenesis in human fibroblasts stimulated with platelet-derived growth factor. J Biol Chem1984; 259: 1546–51.
21.
ViganoT., HernandezA., CorsiniA.. Mevalonate pathway and isoprenoids regulate human bronchial myocyte proliferation. Eur J Pharmacol1995; 291: 201–3.
22.
CorsiniA., MazzottiM., RaiteriM.Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG CoA reductase. Athero-sclerosis1993; 101: 117–25.
23.
CorsiniA., BerniniF., QuaratoP.Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology1996; 87: 458–68.
24.
CorsiniA., PazzucconiF., PfisterP., PaolettiR., SirtoriC.R.. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin (letter). Lancet1996; 348: 1584.
25.
MotomuraN., SaitoS., FoeghM.L.. HMG CoA reductase inhibitors in organ transplantation. J Nephrol1997; 10: 68–76.
26.
McPhersonR., TsoukasC., BainesM.G.. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol1993; 13: 439–44.
27.
KobashigawaJ.A., KatznelsonS., LaksH.Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med1995; 333: 621–7.
28.
TottermanT.H., HanasE., BergstromR., LarssonE., TufversonF.. Immunologic diagnosis of kidney rejection using FACS analysis of graft-infiltrating functional and activated T and NK cell subjects. Transplantation1989; 47: 817–23.
29.
KirbyJ.A., GivanA.L., ShentonB.K.. Renal allograft rejection: possible involvement of antibody-dependent cell-mediated cytotoxicity. Transplantation1990; 50: 225–9.
30.
CuttsJ.L., ScallenT.J., WatsonJ., BankhurstA.D.. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol1989; 139: 550–7.
31.
CuttsJ.L., BankhurstA.D.. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol1990, 145: 244–52.
32.
ScoppolaA., LalaA., MenzingerG.. Effects of different hormones on mevalonic acid and circadian rhythm of cholesterol synthesis. Diabetes Nutrition Metabolism1992; 5: 151–5.
33.
ScoppolaA., TestaG., FrontoniS.The effects of insulin on cholesterol synthesis in type II diabetesCare1995; 18: 1362–9.
34.
NaoumovaR.P., MaraisA.D., MountneyJ.Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG CoA reductase inhibitors in familial hypercholesterolemia. Atheroscelrosis1996; 119: 203–13.
35.
McNamaraD.J., AhrensE.H., ParkerT.S.. Role of the kidneys in the metabolim of plasma mevalonate. J Clin Invest1985; 76: 31–9.
36.
KopitoR.K., BrunengraderH.. (R)-mevalonate excretion in human and rat urines. Proc Natl Acad Sci USA1980; 77: 5738–40.
37.
ScoppolaA., De PaolisP., MenzingerG., LalaA., Di GiulioS.. Plasma mevalonate concentrations in uremic patients. Kidney Int1997; 5: 908–12.
38.
O'DonnelM.P., KasiskeB.L., SchmitzP.G.. Contrasting effects of lovastatin and enalapril on glomerular injury in Dahl salt-sensitive rats. Kidney Int1990; 37: 391.
39.
RoulletJ.B., XueH., ChapmanJ.Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J Clin Invest1996; 97: 2384–90.
